Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.
INTRODUCTION:Primary graft dysfunction (PGD) is a significant contributor to early morbidity and mortality after lung transplantation. Increased vascular permeability in the allograft has been identified as a possible mechanism leading to PGD. Angiopoietin-2 serves as a partial antagonist to the Tie...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3526525?pdf=render |
| _version_ | 1818488206878834688 |
|---|---|
| author | Joshua M Diamond Mary K Porteous Edward Cantu Nuala J Meyer Rupal J Shah David J Lederer Steven M Kawut James Lee Scarlett L Bellamy Scott M Palmer Vibha N Lama Sangeeta M Bhorade Maria Crespo Ejigayehu Demissie Keith Wille Jonathan Orens Pali D Shah Ann Weinacker David Weill Selim Arcasoy David S Wilkes Lorraine B Ware Jason D Christie Lung Transplant Outcomes Group |
| author_facet | Joshua M Diamond Mary K Porteous Edward Cantu Nuala J Meyer Rupal J Shah David J Lederer Steven M Kawut James Lee Scarlett L Bellamy Scott M Palmer Vibha N Lama Sangeeta M Bhorade Maria Crespo Ejigayehu Demissie Keith Wille Jonathan Orens Pali D Shah Ann Weinacker David Weill Selim Arcasoy David S Wilkes Lorraine B Ware Jason D Christie Lung Transplant Outcomes Group |
| author_sort | Joshua M Diamond |
| collection | DOAJ |
| description | INTRODUCTION:Primary graft dysfunction (PGD) is a significant contributor to early morbidity and mortality after lung transplantation. Increased vascular permeability in the allograft has been identified as a possible mechanism leading to PGD. Angiopoietin-2 serves as a partial antagonist to the Tie-2 receptor and induces increased endothelial permeability. We hypothesized that elevated Ang2 levels would be associated with development of PGD. METHODS:We performed a case-control study, nested within the multi-center Lung Transplant Outcomes Group cohort. Plasma angiopoietin-2 levels were measured pre-transplant and 6 and 24 hours post-reperfusion. The primary outcome was development of grade 3 PGD in the first 72 hours. The association of angiopoietin-2 plasma levels and PGD was evaluated using generalized estimating equations (GEE). RESULTS:There were 40 PGD subjects and 79 non-PGD subjects included for analysis. Twenty-four PGD subjects (40%) and 47 non-PGD subjects (59%) received a transplant for the diagnosis of idiopathic pulmonary fibrosis (IPF). Among all subjects, GEE modeling identified a significant change in angiopoietin-2 level over time in cases compared to controls (p = 0.03). The association between change in angiopoietin-2 level over the perioperative time period was most significant in patients with a pre-operative diagnosis of IPF (p = 0.02); there was no statistically significant correlation between angiopoietin-2 plasma levels and the development of PGD in the subset of patients transplanted for chronic obstructive pulmonary disease (COPD) (p = 0.9). CONCLUSIONS:Angiopoietin-2 levels were significantly associated with the development of PGD after lung transplantation. Further studies examining the regulation of endothelial cell permeability in the pathogenesis of PGD are indicated. |
| first_indexed | 2024-12-10T16:48:00Z |
| format | Article |
| id | doaj.art-25861605064c473f9a7ffb6dd6428564 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T16:48:00Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-25861605064c473f9a7ffb6dd64285642022-12-22T01:40:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5193210.1371/journal.pone.0051932Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.Joshua M DiamondMary K PorteousEdward CantuNuala J MeyerRupal J ShahDavid J LedererSteven M KawutJames LeeScarlett L BellamyScott M PalmerVibha N LamaSangeeta M BhoradeMaria CrespoEjigayehu DemissieKeith WilleJonathan OrensPali D ShahAnn WeinackerDavid WeillSelim ArcasoyDavid S WilkesLorraine B WareJason D ChristieLung Transplant Outcomes GroupINTRODUCTION:Primary graft dysfunction (PGD) is a significant contributor to early morbidity and mortality after lung transplantation. Increased vascular permeability in the allograft has been identified as a possible mechanism leading to PGD. Angiopoietin-2 serves as a partial antagonist to the Tie-2 receptor and induces increased endothelial permeability. We hypothesized that elevated Ang2 levels would be associated with development of PGD. METHODS:We performed a case-control study, nested within the multi-center Lung Transplant Outcomes Group cohort. Plasma angiopoietin-2 levels were measured pre-transplant and 6 and 24 hours post-reperfusion. The primary outcome was development of grade 3 PGD in the first 72 hours. The association of angiopoietin-2 plasma levels and PGD was evaluated using generalized estimating equations (GEE). RESULTS:There were 40 PGD subjects and 79 non-PGD subjects included for analysis. Twenty-four PGD subjects (40%) and 47 non-PGD subjects (59%) received a transplant for the diagnosis of idiopathic pulmonary fibrosis (IPF). Among all subjects, GEE modeling identified a significant change in angiopoietin-2 level over time in cases compared to controls (p = 0.03). The association between change in angiopoietin-2 level over the perioperative time period was most significant in patients with a pre-operative diagnosis of IPF (p = 0.02); there was no statistically significant correlation between angiopoietin-2 plasma levels and the development of PGD in the subset of patients transplanted for chronic obstructive pulmonary disease (COPD) (p = 0.9). CONCLUSIONS:Angiopoietin-2 levels were significantly associated with the development of PGD after lung transplantation. Further studies examining the regulation of endothelial cell permeability in the pathogenesis of PGD are indicated.http://europepmc.org/articles/PMC3526525?pdf=render |
| spellingShingle | Joshua M Diamond Mary K Porteous Edward Cantu Nuala J Meyer Rupal J Shah David J Lederer Steven M Kawut James Lee Scarlett L Bellamy Scott M Palmer Vibha N Lama Sangeeta M Bhorade Maria Crespo Ejigayehu Demissie Keith Wille Jonathan Orens Pali D Shah Ann Weinacker David Weill Selim Arcasoy David S Wilkes Lorraine B Ware Jason D Christie Lung Transplant Outcomes Group Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. PLoS ONE |
| title | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. |
| title_full | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. |
| title_fullStr | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. |
| title_full_unstemmed | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. |
| title_short | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. |
| title_sort | elevated plasma angiopoietin 2 levels and primary graft dysfunction after lung transplantation |
| url | http://europepmc.org/articles/PMC3526525?pdf=render |
| work_keys_str_mv | AT joshuamdiamond elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT marykporteous elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT edwardcantu elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT nualajmeyer elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT rupaljshah elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT davidjlederer elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT stevenmkawut elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT jameslee elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT scarlettlbellamy elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT scottmpalmer elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT vibhanlama elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT sangeetambhorade elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT mariacrespo elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT ejigayehudemissie elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT keithwille elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT jonathanorens elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT palidshah elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT annweinacker elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT davidweill elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT selimarcasoy elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT davidswilkes elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT lorrainebware elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT jasondchristie elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation AT lungtransplantoutcomesgroup elevatedplasmaangiopoietin2levelsandprimarygraftdysfunctionafterlungtransplantation |